Critique of Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation Trial

Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation

ENGAGE TRIAL The ENGAGE AF-TIMI 48 trial was a randomised, double-blind, double-dummy trial published in November 2013 in the New England Journal of Medicine. It compares two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high risk of stroke in AF. The study was conducted at 1393 centres across 46 countries and patients were enrolled between November 2008 and ...

Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.

BACKGROUND AND PURPOSE The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously. METHODS We analyzed the subtypes of cerebrovascula...

Anticoagulation in Atrial Fibrillation

Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, ...

Anticoagulation in atrial fibrillation

Atrial fibrillation (AF) affects approximately 300,000 Australians and has a growing prevalence. It is associated with high rates of death and disability. The majority of people with AF are eligible to be treated with anticoagulant medications, but practice is often inadequate, leaving many people at risk of stroke. Until recently, the only antithrombotics available to prevent stroke in people ...